NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE176493 Query DataSets for GSE176493
Status Public on Jun 26, 2024
Title Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
Summary This SuperSeries is composed of the SubSeries listed below.
 
Overall design Refer to individual Series
 
Citation(s) 38833522
Submission date Jun 09, 2021
Last update date Jun 29, 2024
Contact name Patrick Trojer
E-mail(s) patricktroj@gmail.com
Organization name Constellation Pharmaceuticals
Street address 215 First Street, Suite 200
City Cambridge
State/province Massachusetts
ZIP/Postal code 02142
Country USA
 
Platforms (2)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
GPL20301 Illumina HiSeq 4000 (Homo sapiens)
Samples (252)
GSM5363151 1_EV_DMSO_A
GSM5363152 2_EV_DMSO_B
GSM5363153 3_EV_DMSO_C
This SuperSeries is composed of the following SubSeries:
GSE176358 Transcriptomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression
GSE176362 Transcriptomic change of bladder cancer cell lines treated with CPI-0209 [2]
GSE176477 Epigenomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression
Relations
BioProject PRJNA736424

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE176493_RAW.tar 8.5 Gb (http)(custom) TAR (of BED, BROADPEAK, BW, NARROWPEAK, RESULTS, TXT)
SRA Run SelectorHelp
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap